ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Annual

Cash Flow

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Cash flows from operating activities
Net Income
-51,102
-47,149
-51,508
-43,157
-24,399
Depreciation & amortization
1,016
575
1,744
2,052
1,984
Deferred income taxes
-
-
-
-
-
Stock based compensation
5,493
5,168
4,294
4,479
5,010
Change in working capital
-1,315
1,867
3,699
-2,271
-4,424
Accounts receivable
1,100
1,942
4,609
-2,984
-4,072
Inventory
-2,181
102
920
-1,688
-466
Accounts Payable
-
458
309
-437
-786
Other working capital
-43,072
-29,894
-32,170
-33,115
-21,409
Other non-cash items
5,144
10,550
11,830
10,252
3,325
Net cash provided by operating activites
-40,850
-29,075
-29,765
-29,395
-19,953
Cash flows from investing activities
Investments in property, plant and equipment
-2,222
-819
-2,405
-3,720
-1,456
Acquisitions, net
-
-
-
-
-
Purchases of investments
-45,870
-30,558
-7,565
-996
-7,266
Sales/Maturities of investments
36,600
20,500
-
6,525
16,925
Other investing activites
-
-
-
0
0
Net cash used for investing activites
-11,492
-10,877
-9,970
1,809
8,203
Cash flows from financing activities
Debt repayment
-16,290
-7,718
-3,514
0
-4,534
Common stock issued
74,118
81,525
15,694
179
-
Common stock repurchased
-
-
-
-
-
Dividends Paid
-
-
-
-
-
Other financing activites
-
-
-204
-205
60,969
Net cash used privided by (used for) financing activities
84,140
75,025
12,327
-26
59,634
Net change in cash
31,798
35,073
-27,408
-27,612
47,884
Cash at beginning of period
33,273
53,080
80,310
107,922
60,038
Cash at end of period
65,071
88,153
52,902
80,310
107,922
Free Cash Flow
Operating Cash Flow
-40,850
-29,075
-29,765
-29,395
-19,953
Capital Expenditure
-2,222
-819
-2,405
-3,720
-1,456
Free Cash Flow
-43,072
-29,894
-32,170
-33,115
-21,409